MedTrace Logo

Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics

NCT01632995 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 557

Last updated 2021-11-05

Study results available
· View outcomes & findings →

Summary

This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), administered at sexually transmitted disease (STD) clinics and a community health center in the United States.

Conditions

  • HIV Infections

Interventions

DRUG

FTC 200 mg/TDF 300 mg fixed-dose combination tablet

Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Albert Liu, MD, MPH · San Francisco Department of Public Health

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01632995 on ClinicalTrials.gov